Guideline of guidelines: testosterone therapy for testosterone deficiency
We analysed the guidelines for testosterone therapy (TTh) produced by major international medical societies including: the American Urological Association, European Association of Urology, American Association of Clinical Endocrinologists, British Society for Sexual Medicine, Endocrine Society, Inte...
Gespeichert in:
| Veröffentlicht in: | BJU international 2019-11, Vol.124 (5), p.722-729 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 729 |
|---|---|
| container_issue | 5 |
| container_start_page | 722 |
| container_title | BJU international |
| container_volume | 124 |
| creator | Salter, Carolyn A. Mulhall, John P. |
| description | We analysed the guidelines for testosterone therapy (TTh) produced by major international medical societies including: the American Urological Association, European Association of Urology, American Association of Clinical Endocrinologists, British Society for Sexual Medicine, Endocrine Society, International Society for Sexual Medicine, and the International Society for the Study of the Aging Male, and compared their recommendations.
All the organisations were in general agreement concerning the following key points:
Only men meeting the criteria for testosterone deficiency (TD) should be treated.
Consider screening asymptomatic men with certain conditions that increase the risk of TD.
Exogenous TTh causes impairment of spermatogenesis.
There is no evidence that TTh causes prostate cancer.
Men on TTh require careful laboratory monitoring. |
| doi_str_mv | 10.1111/bju.14899 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2275316155</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275316155</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4199-87332ec34d47e84b0be22398d10ddb5402db7bb0a685e6cf028b26a8cb81ccef3</originalsourceid><addsrcrecordid>eNp1kEtLw0AUhQdRbK0u_ANScKOLtPNKMnGnRatScGPB3ZCZudGUNFNnEiT_3tG0goJ3c18fh8NB6JTgCQk1Vat2QrjIsj00JDzhESf4ZX834ywZoCPvVxiHQxIfogEjnOIspUP0MG9LA1VZw9gW49fd4q_GDfjG-gacDb_mDVy-6caFdb8fBopSl1Dr7hgdFHnl4WTbR2h5d_s8u48WT_OH2fUi0pxkWSRSxihoxg1PQXCFFVDKMmEINkbFHFOjUqVwnogYEl1gKhRNcqGVIFpDwUbootfdOPveBi9yXXoNVZXXYFsvKU1jRhISxwE9_4OubOvq4E5ShlMhEpqKQF32lHbWeweF3LhynbtOEiy_8pUhX_mdb2DPtoqtWoP5IXeBBmDaAx9lBd3_SvLmcdlLfgIxK4TL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2307886278</pqid></control><display><type>article</type><title>Guideline of guidelines: testosterone therapy for testosterone deficiency</title><source>Wiley Online Library All Journals</source><creator>Salter, Carolyn A. ; Mulhall, John P.</creator><creatorcontrib>Salter, Carolyn A. ; Mulhall, John P.</creatorcontrib><description>We analysed the guidelines for testosterone therapy (TTh) produced by major international medical societies including: the American Urological Association, European Association of Urology, American Association of Clinical Endocrinologists, British Society for Sexual Medicine, Endocrine Society, International Society for Sexual Medicine, and the International Society for the Study of the Aging Male, and compared their recommendations.
All the organisations were in general agreement concerning the following key points:
Only men meeting the criteria for testosterone deficiency (TD) should be treated.
Consider screening asymptomatic men with certain conditions that increase the risk of TD.
Exogenous TTh causes impairment of spermatogenesis.
There is no evidence that TTh causes prostate cancer.
Men on TTh require careful laboratory monitoring.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/bju.14899</identifier><identifier>PMID: 31420972</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Aging ; Endocrine therapy ; hypogonadism ; Males ; Prostate cancer ; Spermatogenesis ; Testosterone ; testosterone deficiency ; testosterone therapy</subject><ispartof>BJU international, 2019-11, Vol.124 (5), p.722-729</ispartof><rights>2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd</rights><rights>2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.</rights><rights>BJUI © 2019 BJU International</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4199-87332ec34d47e84b0be22398d10ddb5402db7bb0a685e6cf028b26a8cb81ccef3</citedby><cites>FETCH-LOGICAL-c4199-87332ec34d47e84b0be22398d10ddb5402db7bb0a685e6cf028b26a8cb81ccef3</cites><orcidid>0000-0003-2561-5282</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbju.14899$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbju.14899$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31420972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salter, Carolyn A.</creatorcontrib><creatorcontrib>Mulhall, John P.</creatorcontrib><title>Guideline of guidelines: testosterone therapy for testosterone deficiency</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>We analysed the guidelines for testosterone therapy (TTh) produced by major international medical societies including: the American Urological Association, European Association of Urology, American Association of Clinical Endocrinologists, British Society for Sexual Medicine, Endocrine Society, International Society for Sexual Medicine, and the International Society for the Study of the Aging Male, and compared their recommendations.
All the organisations were in general agreement concerning the following key points:
Only men meeting the criteria for testosterone deficiency (TD) should be treated.
Consider screening asymptomatic men with certain conditions that increase the risk of TD.
Exogenous TTh causes impairment of spermatogenesis.
There is no evidence that TTh causes prostate cancer.
Men on TTh require careful laboratory monitoring.</description><subject>Aging</subject><subject>Endocrine therapy</subject><subject>hypogonadism</subject><subject>Males</subject><subject>Prostate cancer</subject><subject>Spermatogenesis</subject><subject>Testosterone</subject><subject>testosterone deficiency</subject><subject>testosterone therapy</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kEtLw0AUhQdRbK0u_ANScKOLtPNKMnGnRatScGPB3ZCZudGUNFNnEiT_3tG0goJ3c18fh8NB6JTgCQk1Vat2QrjIsj00JDzhESf4ZX834ywZoCPvVxiHQxIfogEjnOIspUP0MG9LA1VZw9gW49fd4q_GDfjG-gacDb_mDVy-6caFdb8fBopSl1Dr7hgdFHnl4WTbR2h5d_s8u48WT_OH2fUi0pxkWSRSxihoxg1PQXCFFVDKMmEINkbFHFOjUqVwnogYEl1gKhRNcqGVIFpDwUbootfdOPveBi9yXXoNVZXXYFsvKU1jRhISxwE9_4OubOvq4E5ShlMhEpqKQF32lHbWeweF3LhynbtOEiy_8pUhX_mdb2DPtoqtWoP5IXeBBmDaAx9lBd3_SvLmcdlLfgIxK4TL</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Salter, Carolyn A.</creator><creator>Mulhall, John P.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2561-5282</orcidid></search><sort><creationdate>201911</creationdate><title>Guideline of guidelines: testosterone therapy for testosterone deficiency</title><author>Salter, Carolyn A. ; Mulhall, John P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4199-87332ec34d47e84b0be22398d10ddb5402db7bb0a685e6cf028b26a8cb81ccef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aging</topic><topic>Endocrine therapy</topic><topic>hypogonadism</topic><topic>Males</topic><topic>Prostate cancer</topic><topic>Spermatogenesis</topic><topic>Testosterone</topic><topic>testosterone deficiency</topic><topic>testosterone therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salter, Carolyn A.</creatorcontrib><creatorcontrib>Mulhall, John P.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salter, Carolyn A.</au><au>Mulhall, John P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Guideline of guidelines: testosterone therapy for testosterone deficiency</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2019-11</date><risdate>2019</risdate><volume>124</volume><issue>5</issue><spage>722</spage><epage>729</epage><pages>722-729</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>We analysed the guidelines for testosterone therapy (TTh) produced by major international medical societies including: the American Urological Association, European Association of Urology, American Association of Clinical Endocrinologists, British Society for Sexual Medicine, Endocrine Society, International Society for Sexual Medicine, and the International Society for the Study of the Aging Male, and compared their recommendations.
All the organisations were in general agreement concerning the following key points:
Only men meeting the criteria for testosterone deficiency (TD) should be treated.
Consider screening asymptomatic men with certain conditions that increase the risk of TD.
Exogenous TTh causes impairment of spermatogenesis.
There is no evidence that TTh causes prostate cancer.
Men on TTh require careful laboratory monitoring.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31420972</pmid><doi>10.1111/bju.14899</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-2561-5282</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2019-11, Vol.124 (5), p.722-729 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2275316155 |
| source | Wiley Online Library All Journals |
| subjects | Aging Endocrine therapy hypogonadism Males Prostate cancer Spermatogenesis Testosterone testosterone deficiency testosterone therapy |
| title | Guideline of guidelines: testosterone therapy for testosterone deficiency |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T20%3A38%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Guideline%20of%20guidelines:%20testosterone%20therapy%20for%20testosterone%20deficiency&rft.jtitle=BJU%20international&rft.au=Salter,%20Carolyn%20A.&rft.date=2019-11&rft.volume=124&rft.issue=5&rft.spage=722&rft.epage=729&rft.pages=722-729&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/bju.14899&rft_dat=%3Cproquest_cross%3E2275316155%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2307886278&rft_id=info:pmid/31420972&rfr_iscdi=true |